[96a5a0]: / output / allTrials / identified / NCT05036291_identified.json

Download this file

453 lines (453 with data), 19.1 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
{
"info": {
"nct_id": "NCT05036291",
"official_title": "A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB004 Administered As Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumors",
"inclusion_criteria": "1. males or females of any race>(=)18 years age.\n2. Histologically and/or cytologically confirmed diagnosis of advanced solid tumors that are without standard treatment options (part 1).\n\n Pathologically confirmed locally advanced or metastatic solid tumors with KRAS G12C mutation as determined by a test that has been approved by FDA or local health authority (part 2&3).\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n4. Life expectancy>(=)12 weeks.\n5. Adequate organ and marrow function.\n6. Measurable or evaluable disease.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "1. Prior anti-cancer therapy within 2 weeks or at least 5 half-lives, whichever is longer, up to a maximum of 3 weeks, before the first dose.\n2. Toxicities from previous anti-cancer therapy that have not recovered as required.\n3. Brain metastatic disease, spinal cord compression, or leptomeningeal carcinomatosis.\n4. Active infection including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV):\n5. Female subjects who are pregnant, or breastfeeding, or planning to become pregnant while in this study or within 3 months after the last dose.\n6. Male subjects who plan to father a child while enrolled in the study or within 3 months after the last dose.\n7. Received prior treatment with a PIM kinase inhibitor.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "1. males or females of any race>(=)18 years age.",
"criterions": [
{
"exact_snippets": "males or females",
"criterion": "gender",
"requirements": [
{
"requirement_type": "allowed_values",
"expected_value": [
"male",
"female"
]
}
]
},
{
"exact_snippets": "any race",
"criterion": "race",
"requirements": [
{
"requirement_type": "allowed_values",
"expected_value": "any"
}
]
},
{
"exact_snippets": "(=)18 years age",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "2. Histologically and/or cytologically confirmed diagnosis of advanced solid tumors that are without standard treatment options (part 1).",
"criterions": [
{
"exact_snippets": "Histologically and/or cytologically confirmed diagnosis",
"criterion": "diagnosis confirmation method",
"requirements": [
{
"requirement_type": "method",
"expected_value": [
"histologically",
"cytologically"
]
}
]
},
{
"exact_snippets": "advanced solid tumors",
"criterion": "tumor type",
"requirements": [
{
"requirement_type": "type",
"expected_value": "advanced solid tumors"
}
]
},
{
"exact_snippets": "without standard treatment options",
"criterion": "treatment options",
"requirements": [
{
"requirement_type": "availability",
"expected_value": false
}
]
}
]
},
{
"line": "Pathologically confirmed locally advanced or metastatic solid tumors with KRAS G12C mutation as determined by a test that has been approved by FDA or local health authority (part 2&3).",
"criterions": [
{
"exact_snippets": "Pathologically confirmed locally advanced or metastatic solid tumors",
"criterion": "solid tumors",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": "pathologically confirmed"
},
{
"requirement_type": "stage",
"expected_value": [
"locally advanced",
"metastatic"
]
}
]
},
{
"exact_snippets": "KRAS G12C mutation",
"criterion": "KRAS mutation",
"requirements": [
{
"requirement_type": "mutation type",
"expected_value": "G12C"
}
]
},
{
"exact_snippets": "as determined by a test that has been approved by FDA or local health authority",
"criterion": "test approval",
"requirements": [
{
"requirement_type": "approval",
"expected_value": [
"FDA",
"local health authority"
]
}
]
}
]
},
{
"line": "3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "value",
"expected_value": [
"0",
"1"
]
}
]
}
]
},
{
"line": "4. Life expectancy>(=)12 weeks.",
"criterions": [
{
"exact_snippets": "Life expectancy>(=)12 weeks.",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 12,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "5. Adequate organ and marrow function.",
"criterions": [
{
"exact_snippets": "Adequate organ and marrow function.",
"criterion": "organ function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "Adequate organ and marrow function.",
"criterion": "marrow function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "6. Measurable or evaluable disease.",
"criterions": [
{
"exact_snippets": "Measurable or evaluable disease",
"criterion": "disease",
"requirements": [
{
"requirement_type": "measurability",
"expected_value": [
"measurable",
"evaluable"
]
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "1. Prior anti-cancer therapy within 2 weeks or at least 5 half-lives, whichever is longer, up to a maximum of 3 weeks, before the first dose.",
"criterions": [
{
"exact_snippets": "Prior anti-cancer therapy within 2 weeks or at least 5 half-lives, whichever is longer, up to a maximum of 3 weeks, before the first dose.",
"criterion": "prior anti-cancer therapy",
"requirements": [
{
"requirement_type": "time since last therapy",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 2,
"unit": "weeks"
},
{
"operator": ">=",
"value": 5,
"unit": "half-lives"
},
{
"operator": "<=",
"value": 3,
"unit": "weeks"
}
]
}
}
]
}
]
},
{
"line": "2. Toxicities from previous anti-cancer therapy that have not recovered as required.",
"criterions": [
{
"exact_snippets": "Toxicities from previous anti-cancer therapy that have not recovered",
"criterion": "toxicities from previous anti-cancer therapy",
"requirements": [
{
"requirement_type": "recovery",
"expected_value": true
}
]
}
]
},
{
"line": "3. Brain metastatic disease, spinal cord compression, or leptomeningeal carcinomatosis.",
"criterions": [
{
"exact_snippets": "Brain metastatic disease",
"criterion": "brain metastatic disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "spinal cord compression",
"criterion": "spinal cord compression",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "leptomeningeal carcinomatosis",
"criterion": "leptomeningeal carcinomatosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "4. Active infection including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV):",
"criterions": [
{
"exact_snippets": "Active infection including hepatitis B",
"criterion": "hepatitis B infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Active infection including ... hepatitis C",
"criterion": "hepatitis C infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Active infection including ... human immunodeficiency virus (HIV)",
"criterion": "HIV infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "5. Female subjects who are pregnant, or breastfeeding, or planning to become pregnant while in this study or within 3 months after the last dose.",
"criterions": [
{
"exact_snippets": "Female subjects who are pregnant",
"criterion": "pregnancy status",
"requirements": [
{
"requirement_type": "status",
"expected_value": false
}
]
},
{
"exact_snippets": "breastfeeding",
"criterion": "breastfeeding status",
"requirements": [
{
"requirement_type": "status",
"expected_value": false
}
]
},
{
"exact_snippets": "planning to become pregnant while in this study or within 3 months after the last dose",
"criterion": "pregnancy planning",
"requirements": [
{
"requirement_type": "status",
"expected_value": false
}
]
}
]
},
{
"line": "6. Male subjects who plan to father a child while enrolled in the study or within 3 months after the last dose.",
"criterions": [
{
"exact_snippets": "Male subjects",
"criterion": "gender",
"requirements": [
{
"requirement_type": "presence",
"expected_value": "male"
}
]
},
{
"exact_snippets": "plan to father a child while enrolled in the study or within 3 months after the last dose",
"criterion": "reproductive plans",
"requirements": [
{
"requirement_type": "intention",
"expected_value": "plan to father a child"
},
{
"requirement_type": "timeframe",
"expected_value": "while enrolled in the study or within 3 months after the last dose"
}
]
}
]
},
{
"line": "7. Received prior treatment with a PIM kinase inhibitor.",
"criterions": [
{
"exact_snippets": "Received prior treatment with a PIM kinase inhibitor",
"criterion": "prior treatment with a PIM kinase inhibitor",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}